Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 36,100 shares, a drop of 23.2% from the February 13th total of 47,000 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 830,300 shares, the days-to-cover ratio is currently 0.0 days.

Biodexa Pharmaceuticals Trading Up 11.6 %

BDRX stock opened at $2.12 on Tuesday. Biodexa Pharmaceuticals has a one year low of $1.84 and a one year high of $74.00. The business’s 50 day simple moving average is $3.86.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.